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2ABSTRACT
The potential of gas chromatography / tandem mass spectrometry with triple quadrupole 
analyzer for determination of 12 polybrominated diphenyl ethers in human breast 
tissues has been investigated. After extraction with hexane, two purification procedures 
-automated normal-phase HPLC and solid phase extraction – were assayed. Both 
electron impact ionization, in selected reaction monitoring mode, and negative chemical 
ionization, in selected ion recording mode, were tested for the optimum determination 
of analytes. Isotopically labelled standards were added before extraction as surrogates: 
[13C] BDE47, [13C] BDE99 and [13C] BDE153 for EI, and  p,p’-DDE-D8 for NCI.
The method was validated in terms of accuracy, precision, limits of detection and limits 
of quantification, using human breast tissue spiked at three levels in the range 1-50 ng/g 
(5-250 ng/g for BDE 209). The analytical approach using SPE clean-up followed by 
GC-MS (NCI) led to lower detection limits (0.006-2 ng/g) and allowed the 
determination of the most problematic congener, BDE 209, whose poor sensitivity made 
difficult its determination at low residue levels. Special attention was given to the 
confirmation of the compounds detected in samples in order to avoid reporting false 
positives. Two MS/MS transitions or three m/z ions were selected for each analyte 
when using EI or NCI modes, respectively. In both cases, the transition/ion intensity 
ratio was used as confirmation parameter. The developed methodology was applied to 
the analysis of real human samples. Several BDEs (BDEs congeners 47, 100, 99, 154, 
153 183 and 209) were detected in the range of 0.08-0.23 ng/g.                
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4INTRODUCTION
Polybrominated diphenyl ethers (PBDEs) are structurally similar to polychlorinated 
biphenyls (PCBs) and polybrominated biphenyls (PBBs). They have a large number of 
congeners depending on the number and the position of the halogenated atoms on the 
two-phenyl rings. The total number of possible congeners of PBDEs is 209, going from 
mono to deca BDEs. These compounds have been widely used as reactive flame 
retardants in different consumer products and electronics [1]. Toxicity studies show that 
environmental concentrations of PBDEs can produce thyroid hormone disruption, affect 
learning and memory functions in adults and induce developmental neurotoxic effects 
[2-4]. Estrogenic effects of PBDEs have also been reported [5]. So, these compounds 
are potentially negative for human health.
The resistance of PBDEs to degradation and their high lipid solubility are the cause of 
their persistence and bioaccumulation in the environment and along the food chain. 
PBDEs have been studied in different environmental samples like water, air particles, 
soil, sediments, and sewage sludge samples [6]. The presence of BDEs in biotic samples 
has been reported by several authors. These compounds have been detected in animal 
tissues, including dolphin, seal and whale [7] and human biological samples as serum 
[8, 9], maternal milk [10, 11] and adipose tissues [8, 12-14]. In many cases, the 
concentrations of PBDEs were reported to be increasing over time.
Typically, tri- to hepta-BDEs have been detected in biological samples, including 
human adipose tissues [15, 16]. Although BDE209 has been found in serum and in 
human adipose samples, the concentrations reported are normally at ng/g or sub-ng/g 
levels [9, 11], its determination being difficult due to the decomposition in lower 
congeners and to its poor gastrointestinal adsorption [7]; thus, high sensitive methods 
are required to search BDE209 in human samples. Several reviews about the analysis of 
Page 4 of 35Analytical & Bioanalytical Chemistry
5PBDEs in different types of samples have been published in the last five years [17-19]. 
Most recently, Covaci et. al. [6] have reviewed new developments in the analysis of 
PBDEs. 
The determination of PBDEs in fatty samples usually requires a first sample 
pretreatment to dissolve the lipids in an appropriate solvent, followed by their 
extraction, which can be carried out by LLE or SLE with apolar solvents [9], Soxhet 
extraction [20], column extraction with a mixture of apolar solvents [21] or sonication 
with appropriate solvent [22]. Alternative enhanced extraction techniques, such as 
pressurized liquid extraction or microwave assisted extraction have also been used [23, 
24]. The complexity of extracts requires further purification which can be made by gel 
permeation chromatography [25, 26], Florisil or acidified silica gel column 
chromatography [27-29], and automated normal-phase HPLC [30].
Nowadays, the most usual technique for the analysis of PBDEs is GC-MS. The 
selection of characteristics of the GC-system (stationary phase, column length, injection 
technique…) has a strong influence on the accuracy and precision of the analysis [31]. 
So, if chromatographic conditions are not correctly selected, low yields for nona- and 
deca-BDEs and poor precision for congeners with more than five bromine atoms can be 
obtained.
GC-MS methods using both EI [12, 20, 32] and NCI [25, 26, 33] have been proposed 
for the determination of PBDEs. However, several potential chromatographic 
interferences can hamper good quality data [6]. Thus, when working in EI-MS potential 
interferences originate from chlorinated compounds, like PCBs. When using NCI-MS, 
where only [Br]- ions are monitored, other brominated compounds might also interfere 
with the PBDEs determination. High resolution mass spectrometry (HRMS) is a good 
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6option [34] to reach high sensitivity, selectivity and accuracy but at a considerable 
higher cost. 
Tandem mass spectrometry (MS/MS), using ion trap detectors (ITD) or triple 
quadrupole (QqQ) analyzers, can be an interesting alternative to high resolution devices 
due to the specificity of MS/MS, which allows an improvement in selectivity and also in 
sensitivity [8, 30, 35]. Whereas ITD has been used for the trace analysis of PBDEs in 
differents types of samples [8, 34], GC-MS/MS with QqQ analyzer has been rarely 
explored for the analysis of PBDEs in human samples, where high sensitive techniques 
are required. The use of QqQ in selected reaction monitoring (SRM) mode provides one 
of the most sensitive and selective techniques for the analysis of organic contaminants 
especially at low concentrations.
In the last years, GC-MS/MS with QqQ has been mainly applied to the determination of 
pesticides in fruits and vegetables [36-38] and in food samples [39-41] as well as 
several organic pollutants in environmental samples [35, 42], providing excellent 
sensitivity, selectivity and gain on analysis time, and  allowing the simultaneous 
determination, and confirmation of quite different target analytes. Recently, our own 
research group has also proved the efficiency of this technique for the reliable 
determination of organic pollutants in water [35] and xenoestrogen compounds in 
human breast tissues [30]. 
The aim of this work is the development of analytical methodology for the sensitive 
determination and identification of PBDEs in human breast tissues based on the use of 
GC-MS/MS with QqQ analyzer. The PBDEs congeners most frequently detected 
((BDEs congeners 28, 47, 66, 71, 85, 99, 100, 138, 153, 154, 183 and 209) have been 
included in the study. The application of two different clean-up procedures, based on 
normal phase HPLC and SPE, and the use of EI and NCI modes are investigated.
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7EXPERIMENTAL
Reagents and chemicals
Polibrominated Diphenyl Ether Analytical Standard Mixture “Lake Michigan Study”, 
containing one triBDE (BDE28), two tetraBDEs (BDE 47 and 66), three pentaBDEs 
(BDE 85, 99 and 100) and three hexaBDEs (BDE 138, 153 and 154) (ca. 50 µg/mL in 
isooctane) was purchased from Chiron (Trondheim, Norway). Individual standards of 
BDE 71 (tetraBDE) and BDE 183 (heptaBDE) (50 µg/mL in isooctane each one) were 
supplied by Chiron, whereas BDE 209 (decaBDE) (50 µg/mL in isooctane:toluene  
(9:1) ) was provided by Accustandard (New Haven, USA).
A standard mixture solution containing these 12 BDEs at a concentration level around 
2.5 µg/mL, (except BDE209, at 5 µg/mL) was prepared in hexane and stored at 4° C. 
Working solutions were prepared by diluting this solution in hexane and stored at 4 ºC. 
Two solutions of labeled compounds were used as surrogates. In EI experiments, a 
mixture containing one tetraBDE ([13C] BDE47), one pentaBDE ([13C] BDE99) and one 
hexaBDE ([13C] BDE153), all purchased from Wellington Laboratories (Guelph, 
Ontario, Canada), was used. In NCI experiments, p,p’-DDE-D8, purchased from Dr. 
Ehrenstofer (Augsburg, Germany), was used as surrogate. Working solutions of labeled 
standards (ca. 500 ng/mL for BDEs and 1 µg/mL for DDE) were prepared by dilution of 
the stock solutions with hexane and stored at 4 °C. 
Ethyl acetate and n-hexane (ultra-trace quality) were purchased from Scharlab 
(Barcelona, Spain). Anhydrous sodium sulfate of pesticide residue quality (Scharlab) 
was dried for 18 hours at 300 ° C before use. 
1 g Strata cartridges silica (Phenomenex, USA) were used for SPE.
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8Sample material
Human breast tissues were obtained from women with breast cancer with the exception 
of two samples that corresponded to healthy women. Samples were collected from the 
Oncology Institute of Cancer, at Valencia (FIVO). After collecting the samples, they 
were frozen at approximately -30° C until analysis. A pooled sample obtained by 
mixing several breast tissue samples was used as a “blank” to optimize the analytical 
procedure.
Equipment
LC Instrumentation. The LC system used for sample extracts clean-up was based on our 
previous work [30]. It consisted on a LC Pump Master 305 (Gilson), two six-way high-
pressure valves VICI Valco (Europe Instruments, Schenkon, Switzerland), a sampler 
injector valve Rheodyne (Cotati, CA) with 1.0 mL loop, a silica column Novapack 150 
x 3.9 mm i.d., 4µm (Waters, Mildford, MA), and a fraction collector Gilson FC 203B. 
Mobile phase used was hexane at a flow rate of 1 mL/min.
GC Instrumentation. A GC system (Agilent 6890N, Palo Alto, USA) equipped with an 
autosampler (Agilent 7683) was coupled to a triple quadrupole (QqQ) mass 
spectrometer, Quattro Micro GC (Micromass, Boston, USA), operating in EI and CI 
modes. The GC separation was performed using a DB-1HT capillary column with a 
length of 15 m x 0.25 mm i.d. and a film thickness of 0.1 µm (J&W Scientific, Folson, 
CA, USA). The oven temperature was programmed as follows: 140 ºC (1 min); 10 
ºC/min to 220 ºC; 20 ºC/min to 300 ºC, 40 ºC/min to 340 ºC (5 min) and the injector 
temperature was 260 ºC. Splitless injections of 1 µL sample were carried out. Helium 
99.999% (Carburos Metálicos, Valencia, Spain) was used as carrier gas at a flow of 1 
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9mL/min. The interface temperature was set to 250 ºC and a solvent delay of 3 min was 
selected.
Working in EI, the source temperature was set at 250 ºC and the system operated in 
MS/MS (SRM) mode using argon 99.995% (Carburos Metálicos) as collision gas at a 
pressure of 0.28 Pa in the collision cell. Dwell times/channel between 0.05 to 0.3 s was 
chosen. 
Working in NCI, the source temperature was set at 200ºC and the QqQ system operated 
in SIR mode. Methane 99.9995% (Carburos Metálicos) was used as reagent gas with an 
optimal flow of 60%. 
The application manager Quanlynx was used to process the quantitative data obtained 
from calibration standards and from samples. 
Analytical procedure. Sample preparation and extraction
Samples were thawed at room temperature. Approximately 1 g of tissue sample was 
spiked with 0.5 mL of surrogate labelled solution. The mixture was homogenized with 
5-10 g of anhydrous sodium sulfate and extracted three times with 5 mL of n-hexane 
each time, shaking in a vortex. After filtration, the extract was preconcentrated under a 
gentle nitrogen stream at 40° C, and the final residue was adjusted to 10 mL with n-
hexane.
Clean-up procedures
Two clean-up procedures were investigated. The first one was based on previous work 
carried out in our laboratory [30]. The sample hexanic extract was purified by injecting 
1 mL into the HPLC system. The mobile phase was n-hexane, at a flow rate of 1 
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mL/min. After 16 min, a pulse of 4 mL of modifier solvent (ethyl acetate) was 
introduced. The fraction eluting between minutes 2 and 8 was collected and then it was 
preconcentrated under a gentle nitrogen stream at 40 ° C to dryness, and redisolved in 
0.5 mL of hexane.
The second procedure consisted into a SPE clean-up. 10 mL of the sample hexanic 
extract were passed through the silica SPE cartridge previously conditioned by passing 
6 mL of hexane. The first 3 mL were discarded and the rest -approximately 7 mL- were 
collected together another additional fraction eluted by passing 3 mL of hexane. The 
cleaned-up extract was preconcentrated to dryness under a gentle nitrogen stream at 
40°C and re-dissolved in 0.5 mL hexane.
GC Analysis
The final extracts obtained after clean-up procedure were injected into the Quattro 
Micro GC system working in (EI) MS/MS or in (NCI)MS mode under the experimental 
conditions shown in Tables 1 and 2, respectively. Quantification of samples was carried 
out by using calibration curves prepared with standards in solvent, using relative 
responses to the corresponding labeled internal standards (IS) added as surrogates to the 
samples. Three surrogates were used in EI experiments: [13C] BDE47 for tri- and tetra-
BDEs; [13C] BDE99 for penta-BDEs and [13C] BDE153 for hexa- and hepta-BDEs; 
while in NCI analysis p,p’-DDE-D8 was used as surrogate for all congeners. The 
selection of each IS was made according to its retention/elution behavior in the clean-up 
procedure and to its gas chromatographic retention time.
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Method validation
Validation of the method was performed evaluating the following parameters:
Linearity. The calibration curves were obtained by injecting reference standard 
solutions in duplicate. The concentration range tested was 0.1-40 µg/L for all congeners 
with the exception of BDE 209 (0.5-200 µg/L). Linearity was assumed when regression 
coefficient was >0.99 with residuals lower than 30 %.
Accuracy. It was evaluated by means of recovery experiments, analyzing blank breast 
tissue samples spiked at three levels: 1, 10 and 50 ng/g (5, 50 and 250 ng/g for 
BDE209), (n=5 each level). Previously, the blank sample was analyzed (n=5) to 
determine the analytes’ concentration. 
Precision. Precision, expressed as repeatability of the method, was determined in terms 
of relative standard deviation (R.S.D., in %) from recovery experiments at each 
fortification level (n=5, each).
Limit of Quantification (LOQ). The LOQ was firstly established as the lowest 
concentration that was validated following the overall analytical procedure with 
satisfactory recovery (70-110%) and precision (<20%). However, in NCI analysis, 
where the sensitivity was excellent, this value could be notably lowered leading to a 
more realistic LOQ. In this case, LOQ was statistically estimated for a signal-to-noise 
(S/N) = 10 from the chromatogram of samples spiked at the lowest fortification level 
tested, i.e. 1 ng/g.
Limit of Detection (LOD). The LOD value was estimated, from the quantification 
transition (EI) or ion (NCI), as the analyte concentration that produced a peak signal of 
three times the background noise from the chromatogram at the lowest fortification 
level tested. In the case of analytes showing higher sensitivity (congeners 28, 71, 47, 
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and 100), making the measurement of the noise manually unfeasible, the LOD was 
obtained using a software option for estimating the S/N ratio and referring/recounting 
this value to a S/N value of three.
Limit of confirmation (LOC). The LOC was estimated in the same way than LOD but 
considering the peak signal corresponding to the confirmation transition or ion.
Confirmation criteria. The Q/q ratio, defined as the ratio between the concentration 
obtained from the quantification transition (EI mode) or ion (NCI mode) (Q) and from 
the confirmation transition/ion (q), was used to confirm peak identity in samples. A safe 
confirmation was assumed when the Q/q concentration ratio was found to be between 
0.8 and 1.2, i.e. a maximum tolerance of  ± 20% was accepted to confirm a finding as an 
actual positive. Obviously, the agreement in the retention time in sample and reference 
standard was also required to confirm a positive.
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RESULTS AND DISCUSSION
GC-MS optimization
Optimization of GC-MS methods was performed by injecting hexanic standard 
solutions. First experiments were carried out using a fused-silica HP-5MS capillary 
column (30m x 0.35mm i.d. and 0.25 µm film thickness), but the results for BDE183 
(hepta-brominated) and BDE209 (deca-brominated) were not satisfactory. This was 
probably due to partial or total degradation, as it has been pointed out by several authors 
[33, 43] who recommend the use of shorter columns with thinner film thickness. The 
best results where obtained with a fused-silica capillary column of 15m x 0.25 mm i.d. 
and 0.1 µm film thickness, and using a stationary phase of 100% methyl polisiloxane 
(DB-1HT), which can stand temperatures higher than 300 ºC required to elute higher 
brominated BDEs [44]. 
Using the selected column, the temperature program was optimized in order to achieve a 
satisfactory resolution and peak shape for the twelve PBDEs studied. It was necessary to 
set a high initial temperature (140 ºC) and final ramp (40 ºC/min) in order to avoid
degradation of higher brominated congeners. A final temperature of 340ºC, with a 
holding time of 5 minutes, was required to elute BDE209. 
GC-MS/MS method in EI ionization mode
Optimization of the MS/MS method was performed using triple quadrupole MS 
operating in EI ionization mode. Full scan spectra for all PBDE congeners showed the 
[M]+ and/or [M-Br2]+ isotopic clusters as majoritary ions, so they  were selected as 
precursor ions for every analyte. Different values of collision energy (between 10-60 
eV) were tested to perform the subsequent fragmentation of selected precursor ions. The 
final purpose was to develop a SRM method with at least two MS/MS transitions, 
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normally the most sensitive ones, for each compound in order to have a reliable 
confirmation of the identity of the analyte.
The dwell time parameter was also optimized between 0.05 and 0.3 s in order to obtain 
a good chromatographic peak (with at least 10 points per peak) maintaining satisfactory 
sensitivity for each compound.
Table 1 shows the precursor and product ions corresponding to the quantitative (Q) and 
confirmative (q) transitions monitored in EI ionization mode. Optimum values of 
collision energy were found to be normally around 20 eV for the low brominated 
compounds, increasing for high brominated compounds until values as 50 eV.
Linearity of relative response of analytes was established by analyzing hexanic standard 
solutions, in duplicate, in the ranges 0.4-8 µg/L and 2-40 µg/L. Regression coefficients 
above 0.995 were obtained for all the compounds with residuals lower than 20 %.
GC-MS method in NCI mode
When working in NCI mode it was not feasible to developed a MS/MS method because 
only the clusters from the mass fragments [Br]- and [HBr2]- were observed in the full 
scan spectra. The molecular cluster was not observed or constituted a minor peak; 
therefore, the unique transition feasible for the majority of compounds was the 
fragmentation of [HBr2]- to give a bromine atom, with low sensitivity and poor 
selectivity. As a consequence, a SIR method was optimized monitoring the three most 
intense peaks of the mass spectra, which corresponded to m/z 79 ([79Br]-), m/z 81 
([81Br]) and m/z 161 ([H79Br81Br]). The m/z 79 ion was used for quantification purposes 
and the other two ions were used for confirmation. BDE209 showed a different 
behavior, as its full scan spectra did not show the [H79Br81Br] fragment. For this 
Page 14 of 35Analytical & Bioanalytical Chemistry
15
congener the three most intense peaks were: m/z 79 ([79Br]-) -used for quantification-
and m/z 487 [C6O79Br381Br2]- and m/z 81 ([81Br]-) -used for confirmation.
The NCI method was optimized injecting hexanic standard solutions. Different values 
of source temperature (100-150 ºC), electron energy (30-100 eV), emission current 
(100-500 µA) and methane flow (20-80%) were tested in order to improve the 
sensitivity, the optimum values being 200 ºC, 50 eV, 400 µA and 60%, respectively.   
As the ions monitored in SIR method are the same for isotopically labeled (13C) 
congeners, it was necessary to select another compound as surrogate. Based on the 
results obtained in our previous work [30], p,p’- DDE-D8 was selected for analysis 
performed by NCI. The temperature program was slightly modified, decreasing the 
initial temperature to 120 ºC, in order to elute adequately the new surrogate.
As a summary, Table 2 shows the quantitative (Q) and confirmative (q) m/z ions and 
the dwell time value selected for every compound. 
Linearity of relative response of analytes was tested analyzing hexanic standard 
solutions, in duplicate, in the ranges 0.1-8 µg/L and 2-40 µg/L (2-40 µg/L and 10-200 
µg/L for BDE209). Regression coefficients above 0.995 were obtained for all the 
compounds, except for BDE209 that was 0.993.
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Clean-up optimization
First, we applied a clean-up procedure by automated normal-phase HPLC based on our 
previous work on human adipose tissues analysis [30]. 1 mL hexanic extract (0.1 g 
sample/mL) was injected into the LC-system, and every 1-mL fraction eluted with 
hexane was analyzed in order to determine the presence and recovery of analytes. Data
obtained showed that all compounds and IS were collected in the fractions between 
minutes 2 and 8.
Once optimized the GC-MS measurement, the application of this clean-up procedure led 
to LODs around 5 ng/g. This value was considered too high for real samples; 
consequently, a second clean-up based on the use of SPE silica cartridges was optimized 
in order to improve sensitivity. 10 mL of a mixed hexanic standard solution of PBDEs, 
100  ng/mL each, were loaded into the silica cartridge and every 1-mL fraction, eluted 
with hexane, was analyzed by GC-MS. Data obtained showed that, after discarding the 
first 3 mL, all analytes eluted in the next 10 mL. This procedure was subsequently 
applied to hexanic sample extracts in order to evaluate the fat content in the analytes’ 
fraction, which was found to be approximately 30% of the total amount loaded into the 
cartridge. According to our experience, this amount of fat can be injected into the GC-
MS without relevant damages neither in the chromatographic system or in the MS 
detector.
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Validation results
Sample used in the validation process consisted of a pool of several human adipose 
tissue samples. This sample was previously analyzed (n=5), and any of the BDE 
congeners studied in this work were detected. So it was used as a blank in subsequent 
experiments.
Validation was carried out in terms of precision, accuracy, LOQs and LODs. 
Considering that two transitions or several ions were monitored for a reliable 
identification, both LOCs and Q/q ratios, were also evaluated. Labeled internal 
standards were added at the initial stage of the procedures as quality control (i.e. used as 
surrogates) in order to correct for possible losses along the overall procedure and/or 
instrumental deviations.
EI(MS/MS)procedure
Precision and accuracy were estimated by analyzing five replicate blank samples spiked 
at three concentration levels each: 1, 10 and 50 ng/g. Because of sensitivity differences, 
validation at the lowest level (1 ng/g) was only performed by applying the SPE clean-up 
procedure, while the LC clean-up procedure was applied to the other two levels (10 and 
50 ng/g).
Recoveries were satisfactory, with average values between 70 and 120 % at the three 
levels tested, with the only exception of two congeners (BDE71 and BDE138) at the 
lowest level of fortification (recoveries around 60%). Precision was also satisfactory, 
with R.S.D. lower than 10% in the majority of the cases. (Table 3)
Application of the HPLC automated clean-up did not allow us to reach enough 
sensitivity to analyze real adipose tissue samples, where total PBDE levels found 
usually ranged between 0.3 and 70 ng/g [16]. However, the alternative method of 
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purification based on SPE led to a sensitivity about ten times higher, allowing the 
detection of analytes in real samples. 
LODs were calculated from the quantification transition (Q) and were around 1 ng/g 
(SPE clean-up) or varied between 2-10 ng/g (HPLC clean-up). It can be pointed out that 
LOCs (obtained in a similar way to LOD, but considering the confirmation (q) 
transition) were quite similar to LODs, which means that confirmation of analytes was 
feasible at the same level than their detection. LOQs were established as the lowest 
level validated level (10 and 1 ng/g when using HPLC automated and SPE clean-ups, 
respectively), except for BDE28, whose greater response allows to obtain lower LOQ 
values (5 and 0.3 ng/g, respectively), which were estimated for an S/N=10. These values 
were considered too high for quantification of real samples. In the particular case of 
decabrominated BDE 209, the sensitivity was not sufficient for its determination at lows 
levels, requiring the application of the NCI (MS) mode.
In relation to Q/q concentration ratios, data obtained were excellent at the three levels of 
fortification, ranging between 0.84-1.14 (i.e. deviations bellow ±20%) and R.S.D.s were 
lower than 10%, except for some of the higher brominated congeners, possibly due to 
the lower sensitivity for these compounds.
Figure 1 shows the GC-MS/MS chromatograms for a blank sample fortified at the 
lowest level validated, i. e. 0.1 ng/g (5 ng/g for BDE209), after application of the SPE 
clean-up. As can be seen, BDE209 congener could not be detected at this low level.
NCI (MS) procedure
The use of NCI in the determination of halogenated compounds like PBDEs leads to an 
increase in sensitivity respect to EI ionization, as several authors have reported [14, 17]. 
However, PBDEs MS spectra provides poor information with only two ions (Br- and 
HBr2-), and determination of analytes in this mode may seem not sufficiently specific. It 
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must be pointed out that only a limited number of analytes containing one or more 
bromine atoms can be present in human adipose tissues analyzed by GC and ionized in 
NCI mode [45], so the selectivity for these compounds is relatively high.
Validation of the overall procedure was carried out in a similar way than for EI, using in 
this case p,p´-DDE-D8 as surrogate. Recoveries for BDE209 were quite good (98, 106 
and 109%) without the necessity of the expensive use of [13C]-labelled BDE 209 as 
reported in the literature [6].
Overall data for accuracy and precision were satisfactory at the three fortification levels 
tested, with recoveries between 70 and 110% and RSDs better than 15% for almost all 
compounds. (Table 4)
In relation to LODs, the NCI method led to values around 20 times lower than for EI 
mode, and ranged between 0.006-0.15 ng/g. These values are similar, and in some cases 
suppose an improvement, to data recently published [6, 32, 46]. In the particular case of 
BDE209, the LOD was found to be 0.5 ng/g. LOCs were quite similar to LODs, making 
feasible the confirmation of analytes at the detection level. In relation to LOQs, it seems 
quite evident that concentrations much lower than the lowest level validated (1 ng/g) 
could be quantified in the light of the high sensitivity of the method. In this case, LOQ 
values were estimated for S/N=10 from chromatograms of samples spiked at the lowest 
level tested. Values obtained ranged between 0.02 and 0.5 for tri- to hepta-BDEs, 
allowing the quantification of the concentrations typically found in human adipose 
samples [15, 47]. 
Two set of values of Q/q concentration ratios were obtained: the first (Q/q1) was 
calculated for the ions 79 [79Br]- and 161 [H79Br81Br]- (except for BDE 209, ions 79 and 
487[C6O79Br381Br2]-), and the second (Q/q2) for the ions 79 and 81 [81Br]- for all 
compounds, BDE209 included. Experimental Q/q ratios were satisfactory and ranged 
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between 0.83-1.2, with the exception to BDE85 (1.3); so deviations were below ±20% 
and their RSD were mostly lower than 10%.  
In conclusion, the NCI method led to a considerable improvement in sensitivity, making 
the detection of PBDEs at low levels feasible. As an illustrative example, Figure 2 
shows the SIR chromatograms corresponding to blank sample fortified at 1 ng/g level (5 
ng/g for BD209) after applying the SPE clean-up followed by NCI (MS) analysis.
Application to real samples
The SPE clean-up followed by GC-(NCI) MS procedure was applied to the analysis of 
15 human breast adipose tissue samples. The BDE congeners 47, 100, 99, 154, 153, 183 
and 209 were identified in several samples, which is in accordance with data found in 
the literature [12, 46-48]. BDE 47, BDE99 and BDE153 were the most frequent 
congeners detected, (13, 10 and 14 out of 15 samples analyzed, respectively). BDE 100 
was detected in 5 samples, and BDE 154, BDE 183 and BDE209 only were found in 2 
samples. Concentrations of the mono- to hexa-BDEs ranged between 0.08-0.23 ng/g, 
these values being comparable to concentrations found in adipose tissues from Spanish 
population that ranged between 0.001-3 ng/g [13] and <0.07-6 ng/g [28]. Hepta- and 
deca-BDE could not be quantified because of their low concentrations, although they 
were detected in 2 out of 15 samples analyzed.
Illustrative chromatograms for real samples analyzed are shown in Figure 3. This figure 
illustrates the detection of several PBDEs at low levels. A reliable identification of 
analytes in samples was feasible by means of the Q/q  experimental ratios, which varied 
between 0.84 and 1.2 in all findings
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Moreover, in 12 of the samples analyzed one peak that did not correspond to any of the 
target compounds was observed (retention time 7.99 min). In addition, in four of these 
samples two additional peaks (at 8.94 and 14.59 min) were also present. We assumed 
that these peaks corresponded to BDE congeners not included in the study, although 
their identification was not feasible as reference standards were not available in our 
laboratory. Looking at the retention times, an estimation of the number of bromine 
atoms might be made. The peak at 7.99 min might correspond to a tri-congener, 
whereas the other two peaks might be tetra- and nona-BDEs, respectively. 
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CONCLUSIONS
Efficient and advanced analytical methodology has been developed for the 
determination of 12 BDE congeners, including BDE209, in human breast adipose 
tissues. The most difficult task of this work has been to determine BDE209, due to its 
partial degradation, which requires special chromatographic conditions. 
Firstly a rapid method, based on GC-(EI)MS/MS with QqQ analyzer, has been 
developed for quantification and confirmation of  all congeners studied, except 
BDE209, in one single determination step with chromatographic runs around 19 
minutes. This method was satisfactorily validated in samples spiked at 50 ng/g and 10 
ng/g, which were subjected to automated normal phase HPLC clean-up, previously to 
the GC-MS analysis. The fortification level could be lowered to 1 ng/g when applying a 
SPE clean-up procedure with silica cartridges. Later, a GC-(NCI)MS method was 
developed, which allowed a notable sensitivity improvement. It was validated at the 
same levels, obtaining satisfactory results for all congeners studied, including BDE209. 
The lowest LODs (0.006-0.5 ng/g) were obtained with this method, after performing the 
purification step by SPE. The overall method proposed in this work (extraction with 
hexane followed by SPE clean-up and analyses by GC-(NCI)/MS) was applied to the 
analysis of real human breast tissue samples, leading to the finding of several BDEs at 
low levels. The BDE209 congener, which has been rarely studied and detected in
human samples, was also found in several of the samples analyzed. 
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FIGURE LEGENDS
Figure 1. GC-MS/MS (EI) chromatograms of adipose breast tissue fortified at 1 ng/g 
with selected PBDEs (5 ng/g for BDE209) after application of the SPE clean-up 
procedure. 
Figure 2. GC-MS (NCI) SIR chromatograms of adipose breast tissue fortified at 1 ng/g 
with selected PBDEs (5 ng/g for BDE209) after application of the SPE clean-up 
procedure. 
Figure 3. GC-MS (NCI) SIR chromatograms corresponding to the analysis of four 
human breast adipose tissue samples. Chromatograms for the quantification ion (Q) and 
for the two confirmation ions (q1 and q2) are shown in each sample.
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Table 1. Experimental conditions of the optimized GC-EI(MS/MS) method
tR
(min)
Window 
(min) BDE
Precursor
Ion (m/z)
Product
Ion (m/z) Q/q
b
Collision
Energy 
(eV)
6.4 3-7 28 248 [C12H7O
81Br]
406 [C12H7O79Br281Br]
139 [- CO81Br]
246 [- 79Br81Br]
Q
q
15 
15
8.1
8.3
8.6
8.3
7-9 
71
47
66
47 a
486 [C12H6O79Br281Br2]
326 [C12H6O79Br81Br]
498 [13C12 H6O79Br281Br2]
326 [- 79Br81Br ]
219 [- CO79Br]
338 [- 79Br81Br ]
Q
q
15
20
15
9.7
10.1
10.5
10.1
9-10.5
100
99
85
99 a
566 [C12H5O79Br281Br3]
406 [C12H5O79Br81Br2]
578 [13C12 H5O79Br281Br3]
406 [- 79Br81Br]
297 [- CO81Br]
416 [- 81Br2 ]
Q
q
25
15
20
10.9
11.2
11.6
11.2
10.2-11.9
154
153
138
153 a
644 [C12H4O79Br381Br3]
484 [C12H4O79Br281Br2]
644 [C12H4O79Br381Br3]
484 [C12H4O79Br281Br2]
656 [13C12 H4O79Br381Br3]
484 [- 79Br81Br]
217 [- CO79Br281Br]
484 [- 79Br81Br]
324 [- 79Br81Br]
496 [- 79Br81Br ]
Q
q
Q
q
10
50
10
30
20
12.1 11.7-13 183 562 [C12H3O
79Br381Br2]
722 [C12H3O79Br481Br3]
295 [- CO79Br281Br]
562 [- 79Br81Br ]
Q
q
50
30
- 13-19 209 800 [C12O
79Br481Br4]
960 [C12O79Br581Br5]
640 [- 79Br81Br ]
800 [- 79Br81Br ]
Q
q
45
25
 a: labeled congeners used as surrogates.
b : Q: quantification transition, q: confirmation transition. 
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Table 2. Experimental conditions of the optimized GC-NCI(MS) method
tR
(min)
Window 
(min) BDE
Quantification
Ion (m/z)
Confirmation
Ion (m/z) Dwell(sec)
8.1
7.6 3-9 
 
28
p,p’-DDE-D8 a
79 [79Br]-
289 [C14D835Cl3]-
161 [H79Br81Br]-
81 [81Br]-
q1
q2 0.1
9.8
10.0
10.3
9-10.8
71
47
66
79 [79Br]- 161 [H79Br81Br]-
81 [81Br]-
q1
q2 0.1
11.5
11.8
12.3
10.8-12.6
100
99
85
79 [79Br]- 161 [H79Br81Br]-
81 [81Br]-
 q1
q2 0.1
12.7
13.0
13.4
12.5-14
154
153
138
79 [79Br]- 161 [H79Br81Br]-
81 [81Br]-
q1
q2
0.1
14.0 13.5-15 183 79 [
79Br]- 161 [H79Br81Br]-
81 [81Br]-
q1
q2
0.1
16.5 15-19 209 79 [79Br]- 487[C6O
79Br3 81Br2]-
81 [81Br]-
q1
q2
0.05
a:  used as surrogate.
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Table 3. Validation of the GC-EI-MS/MS method for analysis of BDEs in human breast tissue samples ( n=5, at each fortification level). 
LC clean up SPE clean up
Fortification level Fortification level
   50 ng/g    10 ng/g    1 ng/g
Compound Recovery (R.S.D.) Q/q
a Recovery 
(R.S.D.) Q/q
a LOQ 
(ng/g)
LOC 
(ng/g)
LOD 
(ng/g)
Recovery 
(R.S.D.) Q/q
a LOQ 
(ng/g)
LOC 
(ng/g)
LOD 
(ng/g)
BDE28
BDE71
BDE47
BDE66
BDE100
BDE99
BDE85
BDE154
BDE153
BDE138
BDE183
BDE209
86(8)
95(4)
99(4)
100(5)
94(8)
91(11)
110(6)
113(18)
92(11)
102(16)
100(7)
-
1.01(3)
1.02(0)
0.99(2)
1.02(2)
1.01(2)
0.97(3)
0.91(1)
0.98(11)
0.97(11)
0.98(4)
0.96(9)
-
89(3)
96(9)
93(7)
91(6)
100(5)
92(4)
117(9)
94(17)
101(14)
111(5)
95(14)
-
1.07(3)
1(7)
0.99(5)
1(5)
1.06(6)
1.03(7)
0.88(9)
0.86(14)
1.15(8)
1.02(13)
1.08(8)
-
5
10
10
10
10
10
10
10
10
10
10
-
3
5
5
10
4
6
7
10
10
10
10
-
2
3
3
6
3
3
5
5
8
10 b
10 b
-
72(5)
64(6)
71(2)
77(15)
72(6)
75(12)
82(9)
72(10)
92(12)
61(7)
77(15)
-
1(6)
1.01(10)
1.14(4)
1.05(10)
1.12(7)
1.03(8)
1.04(10)
1.02(17)
0.95(10)
0.84(7)
0.97(13)
-
0.3
1
1
1
1
1
1
1
1
1
1
-
0.3
0.6
0.5
1
0.3
0.4
1
1
1
1
1
-
0.1
0.3
0.2
0.6
0.3
0.4
0.8
0.7
1 b
1 b
1 b
-
a: Average value calculated from Q/q concentration of  five replicates at each level of fortification.   
b:LOD estimated for a S/N = 3 was coincident with the lowest level that was fully validated in spiked samples with satisfactory recovery and precision
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Table 4. Validation of the GC-NCI-MS method for determination of BDEs in human breast tissue samples ( n=5, at each fortification level).
LC clean up SPE clean up
Fortification level Fortification level
   50 ng/ga    10 ng/gb    1 ng/gc
Compound Recovery(R.S.D.) Q/q
d 
1 Q/q d 2 Recovery(R.S.D.) Q/q
d
1 Q/qd2 LOQ(ng/g)
LOC
(ng/g)
LOD
(ng/g)
Recovery 
(R.S.D.) Q/q
d
1 Q/qd2 LOQ (ng/g)
LOC 
(ng/g)
LOD 
(ng/g)
BDE28
BDE71
BDE47
BDE66
BDE100
BDE99
BDE85
BDE154
BDE153
BDE138
BDE183
BDE209
95(6)
94(6)
101(7)
101(8)
98(11)
95(12)
99(15)
107(12)
107(12)
101(15)
101(20)
106(4)
1.15(5)
1.14(7)
1.06(7)
1.09(10)
1.14(8)
1.11(10)
1.13(6)
1.07(6)
1.2(5)
1.11(6)
1.16(8)
0.83(15)
1(2)
1(0)
0.99(0)
1(1)
1(0)
1(1)
1.3(18)
0.99(4)
1(3)
0.97(2)
0.98(1)
1.2(13)
104(5)
99(9)
100(8)
96(8)
95(7)
96(7)
91(6)
89(4)
92(6)
88(5)
80(4)
109(19)
1(5)
1.09(3)
1.09(1)
1.06(3)
1.05(3)
0.97(8)
1.03(9)
1.02(2)
1.04(1)
1.01(5)
0.98(7)
0.9(9)
0.99(1)
0.99(1)
1(1)
1.01(1)
1.01(1)
1.01(1)
1.01(2)
1.01(2)
1.01(2)
1(4)
0.98(6)
0.99(6)
0.2
0.5
1
0.3
0.3
0.3
0.5
0.2
0.3
0.7
0.5
40
0.07
0.09
0.06
0.2
0.1
0.1
0.2
0.07
0.1
0.2
0.3
10.7
0.05
0.045
0.3
0.1
0.1
0.1
0.15
0.05
0.1
0.2
0.15
12.5
72(6)
69(4)
94(12)
87(7)
88(8)
91(11)
78(5)
89(7)
91(11)
77(12)
85(8)
98(16)
0.93(9)
0.97(3)
1.11(4)
0.98(4)
1.07(1)
0.95(4)
1.01(7)
1.09(6)
1.08(2)
0.96(2)
0.99(2)
0.95(7)
1.03(2)
1(2)
1(0)
1.02(3)
1.03(4)
1.01(2)
1.01(2)
1.01(3)
1(3)
1.04(5)
0.96(4)
1.02(9)
0.02
0.07
0.03
0.2
0.02
0.03
0.1
0.02
0.03
0.1
0.5
2
0.02
0.03
0.01
0.05
0.008
0.01
0.03
0.01
0.01
0.03
0.2
1
0.006
0.02
0.01
0.05
0.005
0.01
0.03
0.005
0.01
0.03
0.15
0.5
a
 250 ng/g for BDE209,  b 50 ng/g for BDE209,  c  5 ng/g for BDE209.
d Average value calculated from Q/q concentration of the five replicates for each level of fortification.   
Q/q
 1 =79/161, Q/q 2 =79/81 and Q/q 1 =79/487, Q/q 2 =79/81 for BDE 209.
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Figure 1
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Figure 2
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Figure 3
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